Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Ventilation 66% Improvement Relative Risk Hospitalization 80% Ordinal scale 43% Time to improve one unit.. 30% no CI Recovery 25% Time to viral- 6% c19early.org/t Majeed et al. Curcumin for COVID-19 RCT EARLY TREATMENT Is early treatment with curcumin+combined treatments beneficial for COVID-19? Double-blind RCT 92 patients in India Improved recovery with curcumin+combined treatments (p=0.0043) Majeed et al., Evidence-Based Complementary and .., doi:10.1155/2021/8447545 Favors curcumin Favors control
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive) for COVID-19 Patients
Majeed et al., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545
Majeed et al., A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional.., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 100 patients in India, 50 treated with ImmuActive (curcumin, andrographolides, resveratrol, zinc, selenium, and piperine), showing improved recovery with treatment.
risk of mechanical ventilation, 66.2% lower, RR 0.34, p = 1.00, treatment 0 of 45 (0.0%), control 1 of 47 (2.1%), NNT 47, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 79.7% lower, RR 0.20, p = 0.49, treatment 0 of 45 (0.0%), control 2 of 47 (4.3%), NNT 24, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
relative ordinal scale, 43.0% better, RR 0.57, p = 0.004, treatment 45, control 47, day 28.
relative time to improve one unit on ordinal scale, 30.1% lower, relative time 0.70, treatment 45, control 47.
risk of no recovery, 24.6% lower, RR 0.75, p = 0.08, treatment 26 of 45 (57.8%), control 36 of 47 (76.6%), NNT 5.3, day 28.
time to viral-, 5.8% lower, relative time 0.94, p = 0.47, treatment 45, control 47.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Majeed et al., 11 Oct 2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 4 authors, this trial uses multiple treatments in the treatment arm (combined with andrographolides, resveratrol, zinc, selenium, and piperine) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Abstract: Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2021, Article ID 8447545, 9 pages https://doi.org/10.1155/2021/8447545 Research Article A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActiveTM) for COVID-19 Patients Muhammed Majeed ,1,2 Kalyanam Nagabhushanam ,2 Kalpesh Shah ,1 and Lakshmi Mundkur 1 1 2 Sami-Sabinsa Group Limited, 19/1, 19/2, I Main, II Phase, Peenya Industrial Area, Bangalore, Karnataka 560 058, India Sabinsa Corporation, 20 Lake Drive, East Windsor, Piscataway, NJ 08520, USA Correspondence should be addressed to Kalpesh Shah; kalpesh@clinworld.org Received 9 June 2021; Accepted 15 September 2021; Published 11 October 2021 Academic Editor: Changmin Hu Copyright © 2021 Muhammed Majeed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. SARS-CoV-2 has emerged as a global threat due to its infectivity and rapid transmission. We evaluated the safety and efficacy of herbal and mineral formulation (ImmuActive) as an adjunct therapy in COVID-19 patients. Methods. A randomized, double-blind, placebo-controlled study was conducted in 100 COVID-19 patients in three centers in Southern India, and 92 subjects completed the study. Subjects were followed up until they were discharged from the hospital or for a maximum of 28 days, whichever was earlier. The primary outcome parameters were the mean change and time required to change the ordinal scale of disease severity by one unit. The secondary outcomes were the time required to turn RT-PCR negative or get discharged from the hospital, change in modified Jackson’s Symptom Severity score, and COVID-19 quality of life questionnaire. Results. The ordinal scale at the end of the study was significantly lower in COVID-19 patients supplemented with ImmuActive (0.57) than placebo (1.0), with a p value of 0.0043. The ordinal scale decreased by one unit within 2.35 days in ImmuActive-supplemented patients, while it took 3.36 days in placebo-supplemented patients. Days of hospitalization and time required to turn RT-PCR negative were comparatively lower in the ImmuActive arm than the placebo arm. Change in modified Jackson’s Symptom Severity Score and COVID-19 QOL were significant from screening to the end of the study in both ImmuActive and placebo arms. There were no adverse events observed during the study period. Conclusion. The study results suggest that ImmuActive could be a beneficial and safe adjunct treatment for effectively managing COVID-19 infection symptoms.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit